Skip to Content

Aurora Cannabis Inc ACB

Rating as of

Morningstar’s Analysis

Currency in USD

Economic Moat


Capital Allocation


Lockdown Hits Aurora’s Q3 Hard; Slashing Fair Value Amid Continued Challenges and Massive Dilution

Analyst Note

| Kristoffer Inton |

Similar to what we’ve seen among other Canadian cannabis producers, Aurora’s fiscal third-quarter results suffered heavily from lockdowns to control the COVID-19 pandemic in Canada. Unlike previous lockdowns, most dispensaries were closed to in-person sales and only offered online ordering for pick-up or delivery. As a result, cannabis net revenue declined 21% year over year and 18% sequentially to CAD 55 million. Adjusted EBITDA losses widened sequentially to CAD 24 million from CAD 17 million the second quarter. On the positive side, it’s still narrower than the prior-year quarter loss of CAD 50 million. The year-over-year progress reflects the overhead expense progress Aurora has made.

Read Full Analysis

Company Profile

Business Description

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that include Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ‘71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.

4818 31 Street East, Edmonton International Airport
Edmonton, AB, T9E 0V6, Canada
T +1 844 928-7672
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Most Recent Earnings Mar 31, 2021
Fiscal Year End Jun 30, 2021
Stock Type
Employees 2,380

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.